U.S. Markets closed

Biogen stops developing Tysabri to treat stroke after failed study

Feb 7 (Reuters) - Biogen Inc said on Wednesday it would stop developing Tysabri to treat acute ischemic stroke patients after the drug failed to meet the main goal of a mid-stage study.

Tysabri is already approved to treat multiple sclerosis. (Reporting by Manas Mishra in Bengaluru; Editing by Savio D'Souza)